Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer
暂无分享,去创建一个
S. Mousa | D. Bharali | H. Cui | T. Sudha | Waseem Hariri
[1] A. D'Amico,et al. Association of androgen‐deprivation therapy with excess cardiac‐specific mortality in men with prostate cancer , 2015, BJU international.
[2] K. Nakagawa,et al. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer , 2015, International Journal of Clinical Oncology.
[3] D. Peiffert,et al. Niveaux de preuve des nouvelles techniques de radiothérapie du cancer de la prostate , 2014 .
[4] P. Nelson,et al. Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes , 2014, PloS one.
[5] E. Basch,et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. , 2014, The Lancet. Oncology.
[6] J. Cheville,et al. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy , 2014, Prostate Cancer and Prostatic Disease.
[7] Wen-Jeng Wu,et al. Clinical predictor of survival following docetaxel-based chemotherapy , 2014, Oncology letters.
[8] B. Ristau,et al. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. , 2014, Urologic oncology.
[9] S. Mousa,et al. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. , 2013, Nanomedicine.
[10] M. Stöckle,et al. ICRAC controls the rapid androgen response in human primary prostate epithelial cells and is altered in prostate cancer , 2013, Oncotarget.
[11] Xuan Zhang,et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. , 2012, International journal of oncology.
[12] Omid C. Farokhzad,et al. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. , 2012, ACS nano.
[13] Y. Bansal,et al. MS2/TOF and LC-MS/TOF studies on toremifene to characterize its forced degradation products. , 2011, The Analyst.
[14] S. Tagawa,et al. Prostate-Specific Membrane Antigen-Based Therapeutics , 2011, Advances in urology.
[15] S. Mousa,et al. Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications , 2011, Cancers.
[16] Hong Xu,et al. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. , 2010, ACS nano.
[17] Shaker A. Mousa,et al. Cancer Detection and Treatment: The Role of Nanomedicines , 2009, Molecular biotechnology.
[18] H. Bonkhoff,et al. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. , 2009, European urology.
[19] X. de la Torre,et al. A Mass Spectrometric Approach for the Study of the Metabolism of Clomiphene, Tamoxifen and Toremifene by Liquid Chromatography Time-of-Flight Spectroscopy , 2008, European journal of mass spectrometry.
[20] D. Bostwick,et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. , 2006, The Journal of urology.
[21] F. Marshall,et al. In vivo molecular and cellular imaging with quantum dots. , 2005, Current opinion in biotechnology.
[22] P. Carroll,et al. The relative impact and future burden of prostate cancer in the United States. , 2004, The Journal of urology.
[23] J. Gustafsson,et al. Estrogen signaling: a subtle balance between ER alpha and ER beta. , 2003, Molecular interventions.
[24] Seong-Jin Kim,et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. , 2002, Cancer research.
[25] M. Steiner,et al. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. , 2002, Cancer research.
[26] R L Sokoloff,et al. A dual‐monoclonal sandwich assay for prostate‐specific membrane antigen: Levels in tissues, seminal fluid and urine , 2000, The Prostate.
[27] George L. Wright,et al. Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.
[28] W. Fair,et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.
[29] W. L. Davis,et al. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. , 1990, Cancer research.
[30] D. Peiffert,et al. [What is the level of evidence of new techniques in prostate cancer radiotherapy?]. , 2014, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[31] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[32] V. Sumantran. Cellular chemosensitivity assays: an overview. , 2011, Methods in molecular biology.
[33] Wang Xing-sheng,et al. Overview of Prostate-specific Membrane Antigen , 2010 .
[34] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.